After all, beauty starts from the inside out.
For teams developing oral protein therapeutics, the data offers practical insight into how formulation choices impact stability and release
For research purposes only 122 Treetops Victoria Gardens, Colchester, CO4 9YE [email protected] +447449201766 Newsletter Join our mailing list for research updates, exclusive offers, and the latest news
For approved SGLT2 inhibitors there is on average some 1.52 kg weight loss (placebo-adjusted), for GLP1-RAs 24 kg, and for the combination 35 kg [1723]
For the German and European research market, Bergdorf Bio is a frequently cited source
In these two Phase 3 studies (n=3,680 total), patients are randomized to placebo or oral semaglutide in a 1:1 ratio and assessed using the CDR-SB at 2 years, with follow-up of up to 3 years